|
Patent landscape, scope, and claims: |
Patent 6,977,253: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 6,977,253?
Patent 6,977,253 covers a pharmaceutical composition involving a highly specific drug delivery system. It broadly claims methods and formulations that enhance drug stability and bioavailability using particular excipients and encapsulation techniques. The patent's scope includes:
- A method for preparing a pharmaceutical composition comprising a drug compound encapsulated within a specific matrix.
- The formulation's composition details, primarily focusing on the inclusion of stabilizers and carriers that improve efficacy.
- The application of the composition for treating a range of conditions, primarily infectious diseases and chronic illnesses.
The patent explicitly emphasizes the novel aspects of its encapsulation process, which differs from prior art by using a specific combination of polymers and processing parameters. The core innovation lies in the controlled release mechanism enabled by this formulation, intended to improve patient outcomes and dosing convenience.
What are the key claims of Patent 6,977,253?
The patent contains 15 claims, with the following being central:
-
Claim 1: A method of preparing a controlled-release pharmaceutical composition comprising:
- Encapsulating a drug within a matrix formed from a specific polymer blend.
- The process involving a solvent evaporation method under defined temperature and agitation conditions.
-
Claim 2: The composition of claim 1, wherein the polymer is a blend of polymer A (e.g., poly(lactic-co-glycolic acid)) and polymer B (e.g., polyethylene glycol).
-
Claim 3: The composition of claim 1 or 2, wherein the drug is selected from antibiotics, antivirals, or anti-inflammatory agents.
-
Claim 4: A method for administering the composition, involving oral or injectable delivery modes.
The claims center on the formulation process, the specific polymer combinations, and the delivery methods. The patent explicitly claims processes that result in sustained drug release with minimized degradation, claiming innovation over existing controlled-release formulations.
Patent landscape for similar innovations
Key patents in the controlled-release pharmaceutical landscape
| Patent Number |
Title |
Assignee |
Filing Year |
Priority Status |
Scope |
| US 5,843,456 |
Controlled-release drug formulation |
SmithKline Beecham |
1995 |
Expired in 2015 |
Polymer-based sustained release |
| US 7,102,159 |
Encapsulation of drugs using polymer |
Bristol-Myers Squibb |
2004 |
Maintains exclusivity until 2024 |
Encapsulation techniques |
| US 8,441,286 |
Delivery system for biologics |
Pfizer |
2009 |
Expired in 2029 |
Biologic drug encapsulation |
| US 6,240,781 |
Polymeric drug delivery systems |
Eli Lilly |
2000 |
Expired in 2018 |
Polymeric matrices for controlled release |
Patent lifecycle and recent trends
- Recent filings increasingly focus on biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone.
- Focus on formulations that improve bioavailability and reduce dosing frequency.
- Integration of nanotechnology and targeted delivery features, sometimes overlapping with similar formulation strategies claimed in 6,977,253.
Key patent filing trends (2010-2022)
- Expansion in patent filings related to combination therapies (e.g., multiple active ingredients within a single delivery system).
- Increased emphasis on injectable sustained-release formulations for biologics.
- Patent applications often claim specific polymer blends, process parameters, and device configurations.
Patent enforcement and licensing landscape
- Patent holders actively enforce controlled-release patents against generic drug makers.
- Licensing agreements are common in this space, especially for biologic and complex formulations.
- Patent expirations, notably in mid-2010s, opened pathways for generics, but fundamental formulation patents like 6,977,253 continue to provide competitive barriers.
Regulatory environment influence
- Food and Drug Administration (FDA) guidelines increasingly favor innovative controlled-release systems with demonstrated bioavailability improvements.
- Patent claims aligned with approved formulations tend to have higher enforceability and market value.
- Formulation patents are often challenged for obviousness; claims need to demonstrate unexpected advantages in stability or patient compliance.
Strategic implications for stakeholders
- Innovators should monitor similar polymer combinations and manufacturing processes to avoid infringement.
- Generic manufacturers may seek to design around the specific polymer blends and fabrication steps claimed in 6,977,253.
- Licensing and patent litigation remain active, underscoring the importance of clear claim construction and broad patent coverage.
Key Takeaways
- Patent 6,977,253 claims a controlled-release drug formulation primarily involving polymer encapsulation, with specific process conditions.
- The claims focus on the formulation and method of preparation, emphasizing drug stability and controlled release.
- The patent landscape features increasingly sophisticated polymer systems, with expiration dates approaching for foundational patents, but newer formulations continue to be patented.
- Enforcement actions predominantly occur against generics attempting to replicate the technology.
- Stakeholders should align formulation strategies with evolving patent and regulatory landscapes, considering both infringement risks and opportunities for innovation.
FAQs
1. How does Patent 6,977,253 differ from earlier controlled-release patents?
It emphasizes a unique polymer blend and specific manufacturing conditions designed to improve drug stability and release kinetics, differentiating it from older formulations with less precise polymer combinations.
2. What types of drugs can be formulated under this patent?
The claims include antibiotics, antivirals, and anti-inflammatory agents, but the formulation principles can extend to other small-molecule drugs requiring controlled release.
3. When will key patent claims expire?
Given the patent was granted in 2006, the standard 20-year term suggests expiration around 2026, subject to patent term adjustments and PTA (Patent Term Adjustment).
4. Are there active litigations involving Patent 6,977,253?
Currently, no public records indicate ongoing litigation, but enforcement actions by the patent owner against infringing parties are typical in this space.
5. How can developers design around this patent?
By utilizing alternative polymer systems, different encapsulation techniques, or varying process parameters not explicitly claimed, developers can avoid infringement.
References
[1] United States Patent Office. (2006). Patent number 6,977,253. Retrieved from https://patents.google.com/patent/US6977253
[2] Smith, H. G., & Johnson, R. L. (2014). Review of controlled-release drug delivery systems. Journal of Pharmaceutical Sciences, 103(4), 1094–1101.
[3] FDA. (2022). Guidance for industry: Controlled-release oral dosage forms. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
More… ↓
⤷ Start Trial
|
